DCM
AXSM icon

DAFNA Capital Management’s Axsome Therapeutics AXSM Stock Holding History

DAFNA Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-55,700
Closed -$217K – 77
2017
Q1 		$217K Buy
+55,700
New +$266K 0.18% 65

Other funds holding AXSM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return

DAFNA Capital Management's AXSM Position: Q2 2017 in Review

DAFNA Capital Management sold out of Axsome Therapeutics (AXSM) in Q2 2017, closing a stake of 55,700 shares — an estimated $217K sold.

DAFNA Capital Management first reported a position in AXSM in Q1 2017 and held it in 1 quarter. The position peaked at $217K in Q1 2017. 35 funds tracked by Wall St. Rank hold AXSM as of Q2 2017.

  • DAFNA Capital Management reported no remaining Axsome Therapeutics position as of Q2 2017 after selling out during the quarter.
  • DAFNA Capital Management sold 55,700 Axsome Therapeutics shares in Q2 2017, an estimated $217K.
  • DAFNA Capital Management first reported a position in Axsome Therapeutics in Q1 2017 and held it in 1 quarter.
  • DAFNA Capital Management's Axsome Therapeutics position peaked at $217K in Q1 2017.
  • 35 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2017.

Based on DAFNA Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.